TITLE

Successful treatment of refractory autoimmune thrombocytopenia with rituximab and cyclosporin A in a patient with chronic granulomatous disease

AUTHOR(S)
Treliński, Jacek; Chojnowski, Krzysztof; Kurenko-Deptuch, Magdalena; Kasznicki, Marek; Bernatowska, Ewa; Robak, Tadeusz
PUB. DATE
December 2005
SOURCE
Annals of Hematology;Dec2005, Vol. 84 Issue 12, p835
SOURCE TYPE
Academic Journal
DOC. TYPE
Letter
ABSTRACT
A letter to the editor is presented concerning treatment of refractory autoimmune thrombocytopenia with rituximab and cyclosporin A in a patient with chronic granulomatous disease.
ACCESSION #
19095534

 

Related Articles

  • Hydroxyurea in Essential Thrombocytosis. van Genderen, Perry; Michiels, Jan J. // New England Journal of Medicine;9/21/95, Vol. 333 Issue 12, p802 

    A letter to the editor is presented in response to the article "Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis," by S. Cortelazzo, G. Finazzi and colleagues in the April 27, 1995 issue.

  • Response to Savarino et al. Kalambokis, Georgios; Tsianos, Epameinondas V // American Journal of Gastroenterology;Jun2011, Vol. 106 Issue 6, p1172 

    A response by Georgios Kalambokis and Epameinondas V. Tsianos to a letter to the editor regarding their article "Thrombocytopenia associated with chronic liver disease: effects of rifaximin on platelet count" in the 2010 issue is presented.

  • Small Intestinal Bacterial Overgrowth and Helicobacter pylori: Can They Be Cause of Thrombocytopenia in Patients With Chronic Liver Disease? Savarino, Edoardo; Assandri, Lorenzo; Giannini, Edoardo G; Savarino, Vincenzo // American Journal of Gastroenterology;Jun2011, Vol. 106 Issue 6, p1171 

    A letter to the editor is presented in response to the article "Thrombocytopenia associated with chronic liver disease: effects of rifaximin on platelet count," by G. Kalambokis and E. V. Tsianos in the 2010 issue.

  • Successful rechallenge with anagrelide in a patient with anagrelide-associated cardiomyopathy. Wong, Raymond S. M.; Lam, Lydia W. K.; Cheng, Gregory // Annals of Hematology;Aug2008, Vol. 87 Issue 8, p683 

    A letter to the editor is presented which discusses a case of anagrelide-associated cardiomyopathy rechallenge with anagrelide.

  • Anagrelide for essential thrombocythemia.  // American Family Physician;6/1/1997, Vol. 55 Issue 8, p2874 

    Reports the approval of United States Food and Drug Administration on Anagrelide (Agrylin), a therapy for essential thrombocythemia to reduce the elevated platelet count and the risk of thrombosis. Clinical trials of the therapy; Recommendations from its manufacturers.

  • Correction.  // American Journal of Health-System Pharmacy;7/15/2013, Vol. 70 Issue 14, p1185 

    A correction to the article "Development and Implementation of a Nurse-driven, Sliding-scale Nomogram for Bivalirudin in the Management of Heparin-induced Thrombocytopenia" in the June 1, 2013 issue is presented.

  • Partial portal decompression alleviates thrombocytopenia of portal hypertension. McAllister, Earl; Goode, Sarah // American Surgeon;Feb1995, Vol. 61 Issue 2, p129 

    Evaluates whether the reduction of portal pressures seen in patients undergoing H-graft portacaval shunt (HGPS) is sufficient to relieve the thrombocytopenia seen in patients with portal hypertension. Effectiveness of partial portal decompression using the small diameter HGPS in alleviating...

  • Splenic Radiation for Corticosteroid-resistant Immune Thrombocytopenia. Calverley, David C.; Jones, Glenn W.; Kelton, John G. // Annals of Internal Medicine;6/15/92 Part 1, Vol. 116 Issue 12, p977 

    Presents a study which determined the role of splenic radiation as a treatment for immune thrombocytopenia. Background on idiopathic thrombocytopenic purpura; Clinical characteristics of the participants; Data and methods used; Results and conclusions.

  • Romiplostim and eltrombopag: in a class of their own.  // Hem/Onc Today;3/10/2009, Vol. 10 Issue 5, p1 

    The article reports on the manner in which the thrombopoietin agents romiplostim and eltrombopag have changed the treatment of chronic adult idiopathic thrombocytopenic purpura.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics